BridgeMD
Compares treatment options for Prostatic Neoplasms, Castration-Resistant
Official title A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov ID: NCT07225946
What this study is testing
What is Pasritamig?
Pasritamig is an investigational medicine, being studied as a potential treatment for prostatic neoplasms, castration-resistant.
Also referred to as JNJ-78278343.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of the screening as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or...
- Have progressed on at least 1 novel androgen receptor pathway inhibition (ARPI) but received no more than 2 different ARPI for any stage of disease...
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
You likely can't join if
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose)...
- Prior or concurrent second malignancy (other than the disease under study) because the natural history or treatment could interfere with study...
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
The study team makes the final eligibility decision.
Where it's taking place
- Chandler, Arizona, United States
- Little Rock, Arkansas, United States
- Fountain Valley, California, United States
- La Jolla, California, United States
- Los Angeles, California, United States
- Riverside, California, United States
- San Diego, California, United States
- Santa Monica, California, United States
- Aurora, Colorado, United States
- Grand Junction, Colorado, United States
- Lakewood, Colorado, United States
- Sarasota, Florida, United States
- Atlanta, Georgia, United States
- Lisle, Illinois, United States
- Wichita, Kansas, United States
- Edgewood, Kentucky, United States
- Louisville, Kentucky, United States
- Metairie, Louisiana, United States
- Baltimore, Maryland, United States
- Towson, Maryland, United States
+ 96 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chandler, Arizona, United States; Little Rock, Arkansas, United States; Fountain Valley, California, United States; La Jolla, California, United States; Los Angeles, California, United States; Riverside, California, United States and 110 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.